[Reversible posterior leukoencephalopathy syndrome associated to bevacizumab].
Ortiz-Lopez
Esther M
EM
UGC Medicina Interna, Hospital Juan Ramon Jimenez, 21005 Huelva, España. esthermari_12@hotmail.com
Gonzalez-Nieto
José Antonio
JA
Rojas-Marcos
Iñigo
I
Blanco-Ollero
Alberto
A
D000368:Aged; D020533:Angiogenesis Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D003110:Colonic Neoplasms / Q000473:pathology; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000556:secondary; D008279:Magnetic Resonance Imaging; D008297:Male; D054038:Posterior Leukoencephalopathy Syndrome / Q000139:chemically induced* / Q000473:pathology
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab